INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer’s Disease and NASH
March 11, 2020 09:00 ET
|
INmune Bio, Inc.
LA JOLLA, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to...
INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17
March 05, 2020 09:00 ET
|
INmune Bio, Inc.
LA JOLLA, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today announced...
INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results
February 27, 2020 09:00 ET
|
INmune Bio, Inc.
LA JOLLA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat disease, today...
INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS
February 10, 2020 09:08 ET
|
INmune Bio, Inc.
Grant will fund proof-of-concept studies for XPro1595 therapy LA JOLLA, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments...
INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals
January 02, 2020 09:00 ET
|
INmune Bio, Inc.
LA JOLLA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease,...
INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials
December 17, 2019 09:00 ET
|
INmune Bio, Inc.
Phase II program to focus on women with trastuzumab resistant HER2+ breast cancer LA JOLLA, Calif. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunology company developing therapies...
INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
December 02, 2019 09:00 ET
|
INmune Bio, Inc.
Neuroinflammation targeted in XPro1595 Phase Ib clinical trial LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company...
INmune Bio Inc. to Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference Webinar
November 26, 2019 06:00 ET
|
INmune Bio, Inc.
INmune Bio’s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’s drug development. LA JOLLA, Calif., Nov. 26, 2019 (GLOBE...
INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen
November 19, 2019 09:00 ET
|
INmune Bio, Inc.
LA JOLLA, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease,...
INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update
November 08, 2019 16:00 ET
|
INmune Bio, Inc.
LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to...